Agenus spikes on positive data for its brain cancer vaccine

July 1, 2014 2:45 PM

5 0

Agenus' ($AGEN) vaccine for a deadly form of brain cancer helped extend patients' lives in a single-arm study, the company said, news that sent its shares up as much as 20% on hopes it can find a partner to help it into Phase III.

In the Phase II study, which had no control arm, adding Agenus' Prophage vaccine to the standard of care led to a median overall survival of about 24 months in patients with newly diagnosed glioblastoma multiforme (GBM), the company said, and half of the study's 46 participants survived for two year...

Also read: Deutsche Bank Gets a Much-Needed Boost Working for Big Tobacco

Read more

To category page